Patients
RA
DISEASE, RHEUMATISM, THIGH DISEASE
Patients with RA who had inadequate responses to MTX treatment with or without biological DMARDs (bDMARDs) were enrolled in this study. The detailed eligibility criteria are shown below (ineligibility criteria are described in the 
Subjects over 17 years of age.Subjects willing and able to sign informed consent.Subjects fulfilled either the 1987 revised criteria of the American Rheumatism Association or the 2010 classification criteria of the American College of Rheumatology (ACR)/EULAR.Inadequate response to treatment with oral MTX with or without bDMARDs for at least 8 weeks prior to the first dose of tofacitinib at a dose of 4–16 mg/week.Subjects who have low to high disease activity. Disease activity is defined by Clinical Disease Activity Index (CDAI).Subjects must have discontinued all bDMARDs prior to the first dose of tofacitinib. The washout period for bDMARDs (note: rituximab is not approved for the treatment of RA in Japan) is specified as follows: ≥8 weeks for infliximab, ≥2 weeks for etanercept and ≥4 weeks for other bDMARDs.Subjects must have discontinued non-MTX conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (sulfasalazine, hydroxychloroquine, chloroquine and leflunomide) at least 4 weeks prior to the first dose of tofacitinib.